Rodano, Italy

Jacopo Bonanomi

USPTO Granted Patents = 4 

 

 

Average Co-Inventor Count = 3.2

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2017-2022

Loading Chart...
Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Jacopo Bonanomi

Introduction

Jacopo Bonanomi is a notable inventor based in Rodano, Italy. He has made significant contributions to the field of pharmaceuticals, holding a total of four patents. His work focuses on the synthesis of important compounds that have potential therapeutic applications.

Latest Patents

One of Bonanomi's latest patents is a method for the preparation of pimavanserin base. This process involves converting tert-butyl-N-[(4-propan-2-yloxyphenyl)methyl]carbamate to 1-(isocyanatomethyl)-4-propan-2-yloxybenzene, followed by the addition of N-[(4-fluorophenyl)methyl]-1-methylpiperidin-4-amine to yield pimavanserin base. The final step includes purifying the obtained pimavanserin base to ensure high yield and purity. Another significant patent is an efficient method for the preparation of Cangrelor in salt form. This process includes the preparation and subsequent hydrolysis of an intermediate compound, showcasing Bonanomi's expertise in chemical synthesis.

Career Highlights

Jacopo Bonanomi is currently employed at Olon S.p.a., a company known for its focus on pharmaceutical development and manufacturing. His role at Olon S.p.a. allows him to apply his innovative ideas and contribute to the advancement of drug synthesis.

Collaborations

Throughout his career, Bonanomi has collaborated with talented individuals such as Barbara Novo and Stella Defiore. These collaborations have likely enhanced his research and development efforts, leading to successful patent applications.

Conclusion

Jacopo Bonanomi's work in the field of pharmaceuticals exemplifies the impact of innovation on drug development. His patents reflect a commitment to improving synthesis methods for important therapeutic compounds.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…